frontiers of vascular biology: single-cell technologies, small non-coding RNA therapeutics, and new pharmacological targets.
- Published in:
- European Heart Journal, 2022, v. 43, n. 43, p. 4521, doi. 10.1093/eurheartj/ehac631
- Publication type:
- Article
Works matching IS 0195668X AND DT 2022 AND VI 43 AND IP 43
Results: 14
1
2
SECURE polypill as a strategy at the heart of secondary prevention.
- Published in:
- 2022
- Publication type:
- Letter to the Editor
3
Fndc5/irisin-enriched extracellular vesicles: a new hormonal relay in the regular race against vascular ageing.
- Published in:
- European Heart Journal, 2022, v. 43, n. 43, p. 4596, doi. 10.1093/eurheartj/ehac517
- Publication type:
- Article
4
rare case of native aortic valve thrombosis after radiofrequency ablation.
- Published in:
- 2022
- Publication type:
- Case Study
5
dangling right heart tumour.
- Published in:
- 2022
- Publication type:
- Abstract
6
Small non-coding RNA therapeutics for cardiovascular disease.
- Published in:
- European Heart Journal, 2022, v. 43, n. 43, p. 4548, doi. 10.1093/eurheartj/ehac463
- Publication type:
- Article
7
Panvascular medicine: an emerging discipline focusing on atherosclerotic diseases.
- Published in:
- European Heart Journal, 2022, v. 43, n. 43, p. 4528, doi. 10.1093/eurheartj/ehac448
- Publication type:
- Article
8
Exerkine fibronectin type-III domain-containing protein 5/irisin-enriched extracellular vesicles delay vascular ageing by increasing SIRT6 stability.
- Published in:
- European Heart Journal, 2022, v. 43, n. 43, p. 4579, doi. 10.1093/eurheartj/ehac431
- Publication type:
- Article
9
Artificial intelligence in proteomics: new frontiers from risk prediction to treatment?
- Published in:
- European Heart Journal, 2022, v. 43, n. 43, p. 4525, doi. 10.1093/eurheartj/ehac391
- Publication type:
- Article
10
Antithrombotic therapy in patients undergoing transcatheter aortic valve replacement.
- Published in:
- European Heart Journal, 2022, v. 43, n. 43, p. 4532, doi. 10.1093/eurheartj/ehac290
- Publication type:
- Article
11
Is a genotype-guided therapy the optimal strategy to personalize anti-thrombotic management in patients with acute coronary syndrome?
- Published in:
- European Heart Journal, 2022, v. 43, n. 43, p. 4599, doi. 10.1093/eurheartj/ehac219
- Publication type:
- Article
12
Orchestration of vascular smooth muscle cell plasticity using epigenetic therapy.
- Published in:
- European Heart Journal, 2022, v. 43, n. 43, p. 4577, doi. 10.1093/eurheartj/ehac200
- Publication type:
- Article
13
epigenetic enzyme DOT1L orchestrates vascular smooth muscle cell–monocyte crosstalk and protects against atherosclerosis via the NF-κB pathway.
- Published in:
- European Heart Journal, 2022, v. 43, n. 43, p. 4562, doi. 10.1093/eurheartj/ehac097
- Publication type:
- Article
14
Single-cell technologies to decipher cardiovascular diseases.
- Published in:
- European Heart Journal, 2022, v. 43, n. 43, p. 4536, doi. 10.1093/eurheartj/ehac095
- Publication type:
- Article